BERKELEY, Calif.--(BUSINESS WIRE)--Dynavax Technologies Corporation (Nasdaq:DVAX) announced today preclinical data showing results from a key component of the Company’s novel Universal Flu vaccine candidate. Dynavax’s Universal Flu vaccine is being developed to control influenza by providing protection that is not affected by the annual change in the strain of influenza virus, and has the potential to reduce the dose of standard vaccine. The Company plans to initiate a Phase 1 clinical trial for its Universal Flu vaccine in the second half of 2009.
